Suppr超能文献

高表达的鞘氨醇 1-磷酸受体、S1P1 和 S1P3、鞘氨醇激酶 1 和细胞外信号调节激酶 1/2 与雌激素受体阳性乳腺癌患者对他莫昔芬耐药的发展相关。

High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients.

机构信息

Institute of Cancer, College of Medical, Veterinary and Life Sciences, Section of Surgery, Division of Cancer Studies and Molecular Pathology, Faculty of Medicine, University of Glasgow, Pathology Department, Western Infirmary, Glasgow G31 2ER, UK.

出版信息

Am J Pathol. 2010 Nov;177(5):2205-15. doi: 10.2353/ajpath.2010.100220. Epub 2010 Oct 1.

Abstract

Various studies in cell lines have previously demonstrated that sphingosine kinase 1 (SK1) and extracellular signal-regulated kinase 1/2 (ERK-1/2) interact in an estrogen receptor (ER)-dependent manner to influence both breast cancer cell growth and migration. A cohort of 304 ER-positive breast cancer patients was used to investigate the prognostic significance of sphingosine 1-phosphate (S1P) receptors 1, 2, and 3 (ie, S1P1, S1P2, and S1P3), SK1, and ERK-1/2 expression levels. Expression levels of both SK1 and ERK-1/2 were already available for the cohort, and S1P1, S1P2, and S1P3 levels were established by immunohistochemical analysis. High membrane S1P1 expression was associated with shorter time to recurrence (P=0.008). High cytoplasmic S1P1 and S1P3 expression levels were also associated with shorter disease-specific survival times (P=0.036 and P=0.019, respectively). Those patients with tumors that expressed high levels of both cytoplasmic SK1 and ERK-1/2 had significantly shorter recurrence times than those that expressed low levels of cytoplasmic SK1 and cytoplasmic ERK-1/2 (P=0.00008), with a difference in recurrence time of 10.5 years. Similarly, high cytoplasmic S1P1 and cytoplasmic ERK-1/2 expression levels (P=0.004) and high cytoplasmic S1P3 expression and cytoplasmic ERK-1/2 expression levels (P=0.004) were associated with shorter recurrence times. These results support a model in which the interaction between SK1, S1P1, and/or S1P3 and ERK-1/2 might drive breast cancer progression, and these findings, therefore, warrant further investigation.

摘要

先前的细胞系研究表明,鞘氨醇激酶 1(SK1)和细胞外信号调节激酶 1/2(ERK-1/2)通过雌激素受体(ER)依赖性相互作用影响乳腺癌细胞的生长和迁移。本研究利用 304 例 ER 阳性乳腺癌患者队列来探讨鞘氨醇 1-磷酸(S1P)受体 1、2 和 3(即 S1P1、S1P2 和 S1P3)、SK1 和 ERK-1/2 的表达水平与预后的相关性。本研究队列中已经获得了 SK1 和 ERK-1/2 的表达水平,并且通过免疫组化分析建立了 S1P1、S1P2 和 S1P3 的水平。高膜 S1P1 表达与较短的复发时间相关(P=0.008)。高细胞质 S1P1 和 S1P3 表达水平也与较短的疾病特异性生存时间相关(P=0.036 和 P=0.019)。那些同时表达高水平细胞质 SK1 和 ERK-1/2 的肿瘤患者的复发时间显著短于同时表达低水平细胞质 SK1 和细胞质 ERK-1/2 的患者(P=0.00008),复发时间差异为 10.5 年。同样,高细胞质 S1P1 和细胞质 ERK-1/2 表达水平(P=0.004)和高细胞质 S1P3 表达水平和细胞质 ERK-1/2 表达水平(P=0.004)与较短的复发时间相关。这些结果支持 SK1、S1P1 和/或 S1P3 与 ERK-1/2 相互作用可能驱动乳腺癌进展的模型,因此,这些发现值得进一步研究。

相似文献

5
Sphingosine-1-Phosphate Induces Dose-Dependent Chemotaxis or Fugetaxis of T-ALL Blasts through S1P1 Activation.
PLoS One. 2016 Jan 29;11(1):e0148137. doi: 10.1371/journal.pone.0148137. eCollection 2016.

引用本文的文献

1
Integration of summary data from GWAS and eQTLs studies predicts causality of S1PR1 and breast cancer.
Medicine (Baltimore). 2025 Sep 5;104(36):e44074. doi: 10.1097/MD.0000000000044074.
2
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer.
Int J Mol Sci. 2024 Mar 15;25(6):3354. doi: 10.3390/ijms25063354.
6
Targeting metabolism: A potential strategy for hematological cancer therapy.
World J Clin Cases. 2022 Apr 6;10(10):2990-3004. doi: 10.12998/wjcc.v10.i10.2990.
7
Structural insights into sphingosine-1-phosphate receptor activation.
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2117716119. doi: 10.1073/pnas.2117716119. Epub 2022 Apr 11.
8
Phase 1 Evaluation of C-CS1P1 to Assess Safety and Dosimetry in Human Participants.
J Nucl Med. 2022 Nov;63(11):1775-1782. doi: 10.2967/jnumed.121.263189. Epub 2022 Mar 24.
9
Increased Sphingosine Kinase 1 Expression Is Associated with Poor Prognosis in Human Solid Tumors: A Meta-Analysis.
Dis Markers. 2022 Jan 28;2022:8443932. doi: 10.1155/2022/8443932. eCollection 2022.

本文引用的文献

1
Sphingosine 1-phosphate and cancer.
Nat Rev Cancer. 2010 Jul;10(7):489-503. doi: 10.1038/nrc2875. Epub 2010 Jun 17.
3
Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway.
Endocrinology. 2009 Oct;150(10):4484-92. doi: 10.1210/en.2009-0391. Epub 2009 Aug 25.
4
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
Ann Oncol. 2009 Dec;20(12):1953-8. doi: 10.1093/annonc/mdp263. Epub 2009 Jul 12.
5
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Mol Cancer Res. 2009 Apr;7(4):511-22. doi: 10.1158/1541-7786.MCR-08-0107.
6
Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.
Clin Cancer Res. 2009 Feb 15;15(4):1487-95. doi: 10.1158/1078-0432.CCR-07-4967.
7
Role of sphingolipids in the cytoplasmic signaling of estrogens.
Steroids. 2009 Jul;74(7):562-7. doi: 10.1016/j.steroids.2008.12.014. Epub 2009 Jan 8.
8
Estrogen and progesterone interactive effects in postconfluent MCF-7 cell culture.
Steroids. 2009 Apr-May;74(4-5):410-8. doi: 10.1016/j.steroids.2008.12.010. Epub 2008 Dec 30.
10
Sphingosine 1-phosphate, lysophosphatidic acid and growth factor signaling and termination.
Biochim Biophys Acta. 2008 Sep;1781(9):467-76. doi: 10.1016/j.bbalip.2008.05.004. Epub 2008 Jun 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验